13 results about "Vitamin L2" patented technology

This invention belongs to the field of biotechnology and discloses a recombinant strain of Saccharomyces cerevisiae that enhances the efficient synthesis of vitamin K2 and its application. By heterologously integrating the hepS / T and naphthoquinone cyclotransferase genes (menA) of Bacillus subtilis, four genetically engineered strains were constructed based on the designed MK-7 biosynthetic pathway: YK-1, YK-2, YK-3, and YK-4. YK-1 is an expression strain containing the target genes MenF, MenD, and MenH; YK-2 is an expression strain integrating the target genes MenC, MenE, and MenB on the basis of YK-1; YK-3 is an expression strain integrating the target genes hepS and hepT on the basis of YK-2; and YK-4 is an expression strain integrating the target genes yuxO, MenA, and MenG on the basis of YK-3. YK-4 is the final engineered strain that produces high levels of vitamin K2. The optimal fermentation time was determined by measuring OD600 and yield curves. YK-4 reached its maximum cell concentration in 18 hours, which can effectively shorten the fermentation cycle.

The present application relates to the technical field of nutritional supplement food, more specifically, to a double-protein balanced type of old-age nutritional supplement food and a preparation method thereof. The food comprises calcium, magnesium, zinc, iron, vitamin C, vitamin B6, vitamin E, vitamin B2, sodium selenite, nicotinamide, vitamin D3, vitamin A, vitamin B12, folic acid, vitamin B1 and vitamin K2. The present application is targeted at physiological characteristics and metabolic rules of middle-aged and old people, and scientifically proportioned various vitamins, minerals, essential fatty acids and antioxidant substances required by human body, so as to fully meet daily nutritional requirements of the middle-aged and old people and make up for insufficient dietary intake caused by decreased digestive and absorptive functions.

This invention discloses a desmethylmenoprenone methyltransferase mutant, its construction method, and its applications, belonging to the field of biotechnology. Desmethylmenoprenone methyltransferase is a key enzyme in the MK-7 biosynthetic pathway, responsible for catalyzing the methylation reaction of desmethylmenoprenone to generate a series of methylnaphthoquinone (MK) products, ultimately forming MK-7. This invention, through metabolic network regulation and rational design, successfully obtained 19 single-point mutants, among which 5 mutants showed significantly higher catalytic efficiency than the wild-type enzyme. Experimental results show that the recombinant engineered bacteria constructed based on these mutants exhibit significant advantages in the whole-cell catalytic production of vitamin K2 (MK-7), with MK-7 yield increased by more than 20% compared to the wild-type strain. The excellent catalytic performance of the menG mutant provided by this invention provides strong technical support for the industrial production of vitamin K2, and has broad application prospects and market value.

The present invention provides a pharmaceutical composition for improving the quality of life of the elderly based on vitamin K2, the pharmaceutical composition being composed of composition I and composition II, with a mass part ratio of (0.5-7):1. The present invention also provides a method for preparing the pharmaceutical composition and its application. This pharmaceutical combination has the main effects of anti-cancer and anti-Alzheimer's, and at the same time has the effects of bone strength, osteoporosis improvement, anti-aging, antioxidant, memory and cognition improvement, lipid reduction, liver protection, etc., which can effectively improve the quality of life of the elderly and provide healthy support and protection. The pharmaceutical composition of the present invention has stable activity of each component and high bioavailability, which overcomes the technical defects of current products for the elderly, which have a single function, low absorption and utilization effect, strong gastrointestinal irritation, strong side effects, and poor palatability, and does not have any toxic side effects when taken for a long time.

The disclosure is directed to stabilized aqueous compositions containing calcium (in the form of calcium lactate and calcium gluconate), vitamin D3, and vitamin K2. In addition to calcium, vitamin D3, and vitamin K2, the compositions contain an emulsifier (such as e.g., a polysorbate), an antioxidant (such as e.g., ascorbic acid) and one or more of a sweetener (such as e.g., sucralose and sorbitol), a preservative, a flavoring agent, a pH adjuster, or a combination thereof. The disclosure also includes using the compositions to support bone health.

The application belongs to the technical field of organic synthesis, and relates to a synthesis method of vitamin K2 or a derivative thereof. The synthesis method comprises the following steps: obtaining a compound shown in formula I according to a reaction route shown in the following compound 1 and compound 2; wherein the compound 1 and the compound 2 are subjected to enzyme catalysis reaction (enzymatic reaction) to obtain a compound 3; the enzyme used in the enzyme catalysis reaction is one or more of isopentenyl transferase, geranylgeranyl transferase and heptaprenyl pyrophosphate transferase; and n is a natural number from 0 to 7. The synthesis method has the advantages of shortening a synthesis route, simplifying post-treatment operation, less pollution, mild conditions, high reaction efficiency, low production cost, high product purity and the like.

This invention discloses a synergistic, low-carbohydrate, low-uric acid diet system and its application in regulating hyperuricemia. The basic dietary formula consists of synergistically low-carbohydrate staple foods, low-carbohydrate vegetables, low-purine proteins, low-fructose fruits, special oils, and beverages, formulated according to the three-low standards. The nutritional supplement system includes vitamin D3, MK-7 vitamin K2, magnesium glycine, fish oil, and various minerals. Special preparation methods include micro-fermentation / micro-germination of staple foods, static processing of vegetables, and low-temperature cooking of proteins. Differentiated implementation rules are tailored to different types of hyperuricemia, populations, comorbidities, and complications. All ingredients meet the three-low standards: absorbable net carbohydrates ≤30g / 100g (staple foods) or ≤20g / 100g (non-staple foods), purines ≤50mg / 100g, and fructose ≤5g / 100g. Clinical trials show that the formula of this invention can reduce blood uric acid by 24.76%, improve complications by 91.0%, achieve compliance of 95.0%, and demonstrate good safety.

The application discloses a 1,4-dihydroxy-2-naphthoic acid-polyisoprene transferase mutant, a construction method and application thereof, and belongs to the technical field of biology. Eight 1,4-dihydroxy-2-naphthoic acid-polyisoprene transferase mutants which are significantly superior to wild-type enzymes in catalytic efficiency are obtained through rational design and screening, and a recombinant Escherichia coli based on the mutants is constructed, so that the yield of vitamin K2 produced by the whole cell catalysis of the constructed recombinant bacteria is more than 30% higher than that of a wild-type strain. The excellent catalytic performance of the menA mutant provided by the application provides strong technical support for the industrialized production of vitamin K2, and has wide application prospect and market value.

This invention relates to the field of high-pressure fluid processing equipment technology, and discloses a dynamic high-pressure microjet device for vitamin K2 nanoliposomes. The device includes a base, with a housing fixedly connected to the upper part of the base. A high-pressure pump cylinder is mounted on the right side of the outer surface of the housing. A tubular heat exchanger is mounted on the upper left side of the high-pressure pump cylinder. A connecting seat is mounted on the upper right side of the high-pressure pump cylinder. A feed hopper is mounted on the top of the connecting seat, and a sealing cover is mounted on the top of the feed hopper. An impurity filtration mechanism is installed inside the feed hopper. A heating mechanism is installed outside the high-pressure pump cylinder. A heat dissipation hole is opened on the left side of the outer surface of the housing, and a ventilation mechanism is installed outside the heat dissipation hole. The impurity filtration mechanism includes a metal filter screen disposed inside the feed hopper. This structure can remove undissolved large particles, prevent impurities from entering the precision cavity, avoid microchannel blockage and high-pressure pump wear, and improve the operational stability of the equipment.

The application provides a preparation method of a novel dendritic cell vaccine and application thereof, and particularly discloses a method for preparing improved dendritic cells, which comprises the following steps: culturing the dendritic cells in the presence of vitamin K2, so that the dendritic cells capable of inhibiting cell death caused by tumor antigen sensitization are obtained. The improved dendritic cells can significantly enhance T cell activation and tumor cell killing ability. The application further discloses a novel method for tumor immunotherapy of the dendritic cells combined with a T cell vaccine, an existing tumor vaccine, an immune checkpoint inhibitor or radiotherapy and chemotherapy.

The present invention relates to a prebiotic agent for use in the treatment and / or prevention of vitamin K2 deficiency in a subject. The present invention relates to the use of a prebiotic agent in promoting vitamin K2 production in the gut of a subject.

The application discloses a light-stabilized vitamin K2 composition, which comprises at least one light-stabilized vitamin K2 active substance LSV, and a tocopherol phosphate ester TPM and an aqueous base, wherein the LSV has light stability significantly better than natural MK-7, and retains sufficient biological activity, the TPM self-assembles to form nanovesicles to encapsulate the LSV, the average particle size of the vesicles is 80-200 nm, the PDI is less than 0.30, and the embedding efficiency is greater than or equal to 60%. After the composition is subjected to ICH Q1B standard light, the LSV residue is greater than or equal to 80%, the transdermal penetration is increased by 1.5-2.5 times, and the GGCX-MGP axis can be activated to realize the anti-aging, barrier repair and capillary improvement effects. The application solves the light stabilization problem of natural vitamin K2 through a double light stabilization mechanism of chemical modification and a nano carrier, and has a wide commercial prospect.